Cyclerion Therapeutics (CYCN) EBIAT (2019 - 2025)
Historic EBIAT for Cyclerion Therapeutics (CYCN) over the last 7 years, with Q3 2025 value amounting to -$976000.0.
- Cyclerion Therapeutics' EBIAT fell 3499.31% to -$976000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.2 million, marking a year-over-year increase of 5914.16%. This contributed to the annual value of -$3.1 million for FY2024, which is 7572.46% up from last year.
- Latest data reveals that Cyclerion Therapeutics reported EBIAT of -$976000.0 as of Q3 2025, which was down 3499.31% from -$324000.0 recorded in Q2 2025.
- In the past 5 years, Cyclerion Therapeutics' EBIAT ranged from a high of $44.1 million in Q4 2022 and a low of -$16.2 million during Q2 2021
- Its 5-year average for EBIAT is -$2.9 million, with a median of -$1.8 million in 2023.
- Its EBIAT has fluctuated over the past 5 years, first skyrocketed by 50928.07% in 2022, then tumbled by 10955.59% in 2024.
- Cyclerion Therapeutics' EBIAT (Quarter) stood at -$10.8 million in 2021, then skyrocketed by 509.28% to $44.1 million in 2022, then crashed by 104.07% to -$1.8 million in 2023, then skyrocketed by 129.53% to $530000.0 in 2024, then tumbled by 284.15% to -$976000.0 in 2025.
- Its last three reported values are -$976000.0 in Q3 2025, -$324000.0 for Q2 2025, and -$1.4 million during Q1 2025.